yberk İPLİKÇİ, Özgür EFİLOĞLU, Asıf YILDIRIM

Edoxaban Kullanımına Bağlı Spontan Renal Hematom: Olgu Sunumu

Edoxaban faktör Xa'yı doğrudan baskılayan bir oral antikoagülan ilaçtır. Daha az ilaç etkileşimi ve rutin izleme ihtiyacını ortadan kaldırması nedeniyle; inme profilaksisi, venöz tromboemboli profilaksisi/tedavisi, akut koroner sendromların sekonder profilaksisi için hastalara daha iyi tedavi alternatifleri sağlamıştır. Kullanımı arttıkça klinisyenlerin potansiyel tedavi riskleri ve komplikasyon yönetiminden daha fazla haberdar olmaları gerekmektedir. Bu makalede, atriyal fibrilasyon nedenli inme profilaksisi için edoxaban kullanan hastada gelişen spontan renal hematom bildirilmektedir. Hemodinamik destek sağlanan, görüntülemeler ile izlenen ve multidisipliner açıdan tedavi ve takip kararları alınan hasta tüm çabalara rağmen hayatını kaybetti. Kanama pıhtılaşma değerlerini değiştirmedikleri için acil servise başvuran kanamalı hastalarda bu ilaçların kullanım anamnezi dikkatli alınmalıdır. Vakamızda da gösterildiği gibi kullanımları sırasında gelişebilecek ölümcül komplikasyonlar için tedavi algoritmaları geliştirebilmek için daha geniş vaka serilerine ve olgu sunumlarına ihtiyaç vardır.

Anahtar Kelimeler:

edoksaban, major kanama, böbrek, hematom

Edoxaban-related Spontaneous Renal Hematoma: A Case Report

Edoxaban is an oral anticoagulant drug that directly inhibits factor Xa. It is used for stroke prophylaxis, venous thromboembolism prophylaxis / treatment, and secondary prophylaxis of acute coronary syndromes. Drug interactions with edoxaban are rare and there is no need for routine blood monitoring. Clinicians should be more aware of potential complications and complication management, as they are prescribed quite frequently. In this article, a spontaneous renal hematoma in a patient using edoxaban for atrial fibrillation-induced stroke prophylaxis is reported. The treatment and follow-up decisions were made by the multidisciplinary team and the patient died despite all efforts. The use of these drugs should be carefully questioned in patients with bleeding who apply to the emergency room because they do not change the coagulation parameters. Larger case series and case reports are needed to develop treatment algorithms for fatal complications that may occur during their use.

Keywords:

edoxaban, major bleeding, kidney, hematoma,

PDF

___

Matsushima N, Lee F, Sato T, Weiss D, Mendell J. Bioavailability and Safety of the Factor Xa Inhibitor Edoxaban and the Effects of Quinidine in Healthy Subjects. Clin Pharmacol Drug Dev. 2013;2(4):358-66.
Tran H, Joseph J, Young L, McRae S, Curnow J, Nandurkar H, et al. New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural/bleeding management. Australasian Society of Thrombosis and Haemostasis. Intern Med J. 2014;44(6):525-36.
Schwarb H, Tsakiris DA. New Direct Oral Anticoagulants (DOAC) and Their Use Today. Dent J (Basel). 2016;4(1):5.
Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism. New England Journal of Medicine. 2013;369(15):1406-15.
Giugliano RP, Ruff CT, Wiviott SD, Nordio F, Murphy SA, Kappelhof JA, et al. Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial. Am J Med. 2016;129(8):850-7.e2.
Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955-62.
Kato ET, Giugliano RP, Ruff CT, Koretsune Y, Yamashita T, Kiss RG, et al. Efficacy and Safety of Edoxaban in Elderly Patients With Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial. J Am Heart Assoc. 2016;5(5).
Itagaki H, Katuhiko S. Gallbladder hemorrhage during orally administered edoxaban therapy: a case report. Journal of Medical Case Reports. 2019;13(1):383.
Galbiati G. Successful Cerebral Hemorrhage Control with Prothrombin Complex Concentrate in a Patient on Edoxaban Therapy: A Case Report. J Blood Med. 2020;11:35-8.
Tsai TY, Leu HB, Lo LW, Chen SA, Hsu PF. Spontaneous Hemopericardium Complicated with Hemothorax in a Patient Receiving Edoxaban Therapy: A Case Report. Acta Cardiol Sin. 2019;35(3):342-4.
Saldanha I, Matos R, Orfao T, Santos M. Tympanic Membrane Haematoma in a RivaroxabanTreated Patient: A Case Report. Acta Med Port. 2019;32(6):469-70.
Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, et al. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. New England Journal of Medicine. 2017;378(7):615-24.
Beyer-Westendorf J, Forster K, Pannach S, Ebertz F, Gelbricht V, Thieme C, et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood. 2014;124(6):955-62.
Ha JT, Neuen BL, Cheng LP, Jun M, Toyama T, Gallagher MP, et al. Benefits and Harms of Oral Anticoagulant Therapy in Chronic Kidney Disease: A Systematic Review and Meta-analysis. Ann Intern Med. 2019;171(3):181-9.
Scaglione F. New Oral Anticoagulants: Comparative Pharmacology with Vitamin K Antagonists. Clinical Pharmacokinetics. 2013;52(2):69-82.
Keeling D, Baglin T, Tait C, Watson H, Perry D, Baglin C, et al. Guidelines on oral anticoagulation with warfarin - fourth edition. Br J Haematol. 2011;154(3):311-24.
Choudhury M, Chalil S, Abozguia K. Life-threatening pericardial bleed complicating atrial fibrillation ablation associated with edoxaban therapy successfully managed with prothrombin complex concentrate. HeartRhythm Case Rep. 2019;6(3):163-5.